Answers are grounded in this paper and cite their sources.
In spite of the numerous electrophilic warheads, only a fraction of them is used in current drug discovery projects. Recent studies identified new tractable residues by applying a wider array of warhead chemistries. However, versatile, selective warheads are not available for all targetable amino acids, hence discovery of new warheads for these residues is needed. Broadening the toolbox of the warheads could result in novel inhibitors even for challenging targets developing with significant therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Péczka et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: